The combined effect of markers of disease phenotype (e.g., age, gender, location, perianal disease) and medical therapy (steroid use, early immunosupression) on the probability of disease behaviour change were, however, not studied thus far in the published literature.
A research article published on 28 July in the World Journal of Gastroenterology addresses this question. Members of the Hungarian IBD Study Group led by Dr Peter Laszlo Lakatos from the Semmelweis University investigated 340 well-characterised, unrelated, consecutive CD patients (M/F: 155/185, duration: 9.4 +/- 7.5 years) with a complete clinical follow-up. Medical records including disease phenotype according to the Montreal classification, extraintestinal manifestations, use of medications and surgical events were analysed retrospectively. Patients were interviewed on their smoking habits at the time of diagnosis and during the regular follow-up visits.
They found that perianal disease, current smoking, prior steroid use, early azathioprine or azathioprine/biological therapy are predictors of disease behaviour change in CD patients.
The new data with easily applicable clinical information as presented in the article may assist clinicians in practical decision-making or in choosing the treatment strategy for their CD patients.
From: World Journal of Gastroenterology 2009; 15(28): 3504-3510 http://www.wjgnet.com/1007-9327/15/3504.asp
No comments:
Post a Comment